[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tetanus-diphtheria-acellular-pertussis-tdap\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tetanus-diphtheria-acellular-pertussis-tdap":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100592760","phase-1-a-phase-iii-study-to-evaluate-the-safety-and-immunogenicity-of-gc3111b-in-healthy-adults-100592760",false,"NCT06997627","A Phase I\u002FII Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults","An Open(Part 1), Single-arm(Part 1), Randomized(Part 2), Double-blind(Part 2), Active-controlled(Part 2) Phase I\u002FII Clinical Trial to Evaluate the Safety and Efficacy (Immunogenicity) of GC3111B in Healthy Adults","Inclusion Criteria:\n\n* Healthy adults aged 19 to 64 years old as of the date of written consent.\n* Individuals with no history of vaccination with a vaccine containing diphtheria, tetanus, or pertussis antigens within the past 2 years prior to administration of the investigational product.\n\nExclusion Criteria:\n\n* Individuals who have received a vaccine within 4 weeks prior to administration of the investigational product.\n* Individuals with a history of Tdap vaccination prior to administration of the investigational product.\n* Pregnant and breastfeeding women.\n* Individuals who have participated in other clinical trials involving investigational products\u002Fdevices within 6 months prior to administration of the investigational product.",true,"ALL","19 Years","64 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","This clinical trial consists of two parts: Part 1, which explores safety, and Part 2, which examines both safety and efficacy (immunogenicity). Part 1 is a single-center, open-label, single-group study, while Part 2 is designed as a multicenter, double-blind, randomized, active-controlled trial.",[29],"Tetanus-diphtheria-acellular Pertussis (Tdap)","RECRUITING","2025-07-08",{"date":33,"type":34},"2025-07-10","ACTUAL",{"date":36,"type":34},"2025-06-05",{"date":38,"type":22},"2026-05",{"name":40,"class":41},"GC Biopharma Corp","INDUSTRY"]